IRIS
IANNONE, Florenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.336
AS - Asia 9.081
EU - Europa 8.748
SA - Sud America 2.469
Continente sconosciuto - Info sul continente non disponibili 1.719
AF - Africa 385
OC - Oceania 17
Totale 48.755
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.579
SG - Singapore 3.837
IT - Italia 3.089
BR - Brasile 1.915
CN - Cina 1.894
FR - Francia 1.154
HK - Hong Kong 1.096
SE - Svezia 1.010
RU - Federazione Russa 902
DE - Germania 774
VN - Vietnam 592
FI - Finlandia 575
GB - Regno Unito 490
BD - Bangladesh 319
CA - Canada 307
IN - India 306
AR - Argentina 189
UA - Ucraina 173
ID - Indonesia 140
IQ - Iraq 135
TR - Turchia 123
MX - Messico 121
ZA - Sudafrica 100
JP - Giappone 92
PK - Pakistan 91
EC - Ecuador 88
CI - Costa d'Avorio 82
CO - Colombia 81
ES - Italia 75
BE - Belgio 74
SA - Arabia Saudita 70
VE - Venezuela 68
NL - Olanda 60
IE - Irlanda 59
PL - Polonia 58
AT - Austria 54
CR - Costa Rica 50
PH - Filippine 50
UZ - Uzbekistan 45
MA - Marocco 42
JM - Giamaica 41
TT - Trinidad e Tobago 38
CL - Cile 35
PY - Paraguay 35
HN - Honduras 34
LT - Lituania 32
GT - Guatemala 31
MY - Malesia 30
CW - ???statistics.table.value.countryCode.CW??? 28
CZ - Repubblica Ceca 28
TN - Tunisia 27
KE - Kenya 25
IR - Iran 24
NI - Nicaragua 24
IL - Israele 23
PE - Perù 22
EG - Egitto 21
JO - Giordania 21
PR - Porto Rico 21
SV - El Salvador 21
ET - Etiopia 20
CH - Svizzera 19
GP - Guadalupe 19
BO - Bolivia 17
NP - Nepal 17
DK - Danimarca 16
TH - Thailandia 16
EU - Europa 15
OM - Oman 15
AZ - Azerbaigian 14
KZ - Kazakistan 14
AM - Armenia 13
DZ - Algeria 13
AE - Emirati Arabi Uniti 12
AU - Australia 12
PA - Panama 12
UY - Uruguay 12
BB - Barbados 11
PS - Palestinian Territory 11
RS - Serbia 11
LB - Libano 10
PT - Portogallo 10
AL - Albania 9
BH - Bahrain 9
DO - Repubblica Dominicana 9
KG - Kirghizistan 9
BG - Bulgaria 8
EE - Estonia 8
KR - Corea 8
SC - Seychelles 8
SN - Senegal 8
BS - Bahamas 7
HR - Croazia 7
MD - Moldavia 7
QA - Qatar 7
AO - Angola 6
RO - Romania 6
SI - Slovenia 6
SY - Repubblica araba siriana 6
TW - Taiwan 6
Totale 46.963
Salva come PNG Salva come JPEG
Città #
Ashburn 2.759
Fairfield 2.591
Singapore 2.077
Woodbridge 1.846
San Jose 1.718
Houston 1.425
Chandler 1.366
Milan 1.104
Seattle 1.086
Hong Kong 1.085
Cambridge 936
Ann Arbor 922
Wilmington 817
Nyköping 800
Council Bluffs 617
Beijing 609
Jacksonville 432
Dallas 431
Rome 389
Lauterbourg 384
New York 363
Los Angeles 328
Lawrence 323
Roxbury 311
Helsinki 301
Munich 282
Santa Clara 258
Nanjing 256
Bari 246
Des Moines 204
São Paulo 204
Ho Chi Minh City 180
Columbus 178
Princeton 176
Inglewood 173
Boardman 172
Buffalo 129
Hanoi 126
Falkenstein 120
San Diego 120
Brooklyn 117
London 117
Moscow 114
Chicago 108
Figino 104
Phoenix 91
Abidjan 81
Dearborn 80
Atlanta 79
Turku 79
Paris 75
Shenyang 75
Jakarta 74
Montreal 73
Tokyo 72
Brussels 71
Toronto 67
Turin 63
Frankfurt am Main 62
Rio de Janeiro 62
The Dalles 62
Hebei 59
Denver 57
San Francisco 55
Baghdad 54
Dublin 54
North Bergen 53
Dong Ket 52
Jiaxing 52
Nanchang 51
Boston 50
Johannesburg 50
Naples 50
Warsaw 49
Chennai 48
Belo Horizonte 45
Brasília 44
Orem 44
Dhaka 43
Nuremberg 40
Poplar 40
Mexico City 39
Tianjin 39
Tashkent 38
Changsha 36
Lahore 36
Manchester 36
San José 35
Stockholm 35
Bologna 33
Redwood City 31
Quito 30
Shanghai 30
Washington 30
Bar Harbor 29
Guangzhou 29
Pune 29
Willemstad 28
Guayaquil 27
Kingston 27
Totale 31.177
Salva come PNG Salva come JPEG
Nome #
Orofacial Manifestation of Systemic Sclerosis: A Cross-Sectional Study and Future Prospects of Oral Capillaroscopy 293
Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patients 280
Explainable artificial intelligence for microbiome data analysis in colorectal cancer biomarker identification 250
A rare association of anti-alanine-transfer RNA synthetase (anti-PL12) syndrome and sporadic inclusion body myositis 243
Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group 240
Safety of Long-Term Biologic Therapy in Rheumatologic Patients With a Previously Resolved Hepatitis B Viral Infection 220
Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors 219
A Case of Osteonecrosis of the Jaw in a Patient with Crohn's Disease Treated with Infliximab 209
No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan 204
AB0836 Drug retention rate of the first tnf inhibitor in radiographic and non radiographic axial spondyloarthritis: data from a multicenter study 204
Clinical, histologic and prognostic features of clinically amyopathic dermatomyositis 203
Anti-SAE dermatomyositis: clinical and histologic characteristics from a monocentric Italian cohort 203
A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis 202
Autophagy markers LC3 and p62 accumulate in immune‐mediated necrotizing myopathy 201
Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease 199
A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy 195
AB0618 A unique ultrasound pattern of adipose tissue in systemic sclerosis patients: a comparison with rheumatoid arthritis patients and healthy controls. two sides of adipose tissue involvement in systemic chronic inflammatory diseases 194
Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study 194
Basic characteristics of adults with periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome in comparison with the typical pediatric expression of disease 193
AB0065 Possible Interplay Between Serum Amyloid-A and Pro-Inflammatory Cytokines Into the Pathogenesis of Behçet's Disease 191
AB0452 Changes in Lipoproteins Associated with Tocilizumab Treatment Do not Influence the Atherogenic Index of Plasma of Rheumatoid Arthritis Patients: Table 1 190
Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients 188
AB0041 Serum Amyloid A Stimulates The Induction of Inflammatory Mediators in Monocytes from Behçet's Disease Patients: A Proof of Concept Study 186
Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease 184
Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives 182
Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis 181
Digital ulcers predict a worse disease course in patients with systemic sclerosis 181
Clinical spectrum time course in anti jo-1 positive antisynthetase syndrome: Results from an international retrospective multicenter study 181
Perivascular and endomysial macrophages expressing VEGF and CXCL12 promote angiogenesis in anti-HMGCR immune-mediated necrotizing myopathy 181
Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study 180
Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: Premises, perils, and perspectives 179
Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA 178
Retinal vessels thrombosis as onset manifestation of systemic sclerosis: 3 clinical cases 178
Evaluation of differences in carotid intima-media thickness in patients affected by systemic rheumatic diseases 178
Orofacial Manifestations and Temporomandibular Disorders of Sjogren Syndrome: An Observational Study 177
Nailfold capillaroscopy characteristics of antisynthetase syndrome and possible clinical associations: Results of a multicenter international study 177
Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment 176
Analysis of subchondral cortical plate and trabecular bone in osteoarthritis experimentally induced in goat tibia. Preliminary results 175
Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy 175
Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of Infliximab: A case series and review of the literature 174
Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis 174
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register 173
Possible interplay between interleukin-15 and interleukin-17 into the pathogenesis of idiopathic inflammatory myopathies 173
Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases 173
SAT0216 Chest Ultrasound Signs of Interstitial Lung Disease in Systemic Sclerosis Patients: A Comparison between High Resolution Chest Computed Tomography Findings 173
AB0369 Adult-onset still’s disease treatment predictors at 1-year follow-up in a single rheumatologic centre experience 171
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice 169
Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group 169
Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study 165
A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: A EUSTAR prospective study 164
A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome 163
ANTI-TNFA THERAPY IN PSORIATIC ARTHRITIS: DIFFERENT RATE OF REMISSION IN POLYARTICULAR AND OLIGOARTICULAR SUBSETS 162
Lipid Profile of Rheumatoid Arthritis Patients Treated with Anti-Tumor Necrosis Factor-Alpha Drugs Changes According to Disease Activity and Predicts Clinical Response 161
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: Results from a collaborative project of 11 European biologic registers 161
Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab 161
Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis 160
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients 160
Leucocytoclastic vasculitis as onset symptom of ulcerative colitis 159
Chondrocytes treated with different shock wave devices 159
Auditory involvement in Behcet’s disease: relationship with demographic, clinical, and therapeutic characteristics 159
Different switching rate of anti-TNF-α drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life 157
Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study 156
AN UNWELCOME HOST IN THE PATHOGENESIS OF ARTHRITIDES 155
THU0153 The effect of 5-years b-dmards treatment on different 10-years cardiovascular risk scores applied in rheumatoid arthritispatients 152
Peripheral and central nervous system correlates in fibromyalgia 152
Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate 151
SAT0212 Pericardial Effusion Related To Systemic Sclerosis: A Possible Contribution of The Serum Levels of Adipokines and Interleukines 151
Longterm clinical outcomes in 420 patients with psoriatic arthritis taking anti-tumor necrosis factor drugs in real-world settings 150
Update on laser-evoked potential findings in fibromyalgia patients in light of clinical and skin biopsy features 150
Proinflammatory cytokines and antiskin autoantibodies in patients with inherited epidermolysis bullosa 149
Joint and tendon involvement predict disease progression in systemic sclerosis: A EUSTAR prospective study 149
LIPID PROFILE OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ANTI-TNF-ALPHA DRUGS CHANGES ACCORDING TO DISEASE ACTIVITY RESPONSE 149
ASSOCIATION OF SYSTEMIC SCLEROSIS AND PSORIATIC ARTHRITIS: A CASE REPORT 148
Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab 148
Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis 148
The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts 148
A convolutional neural network with transfer learning for automatic discrimination between low and high-grade synovitis: a pilot study 147
Serum amyloid-A in Behçet's disease 146
Generation of a core set of items to develop classification criteria for Scleroderma renal crisis using consensus methodology 145
PFAPA syndrome and Behçet’s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists 145
Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: A multicenter randomized clinical trial 145
Infliximab therapy in patients with rheumatic disease and HCV chronic infection 145
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study 145
Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis 144
The Impact of Biologic Drugs on High-Density Lipoprotein Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients 143
Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature 142
Update on the profile of the EUSTAR cohort: An analysis of the EULAR Scleroderma Trials and Research group database 142
The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries 141
Evaluation of Serum Levels of Adipokines and Interleukines in Pericardial Effusion Related to Systemic Sclerosis 141
A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab 140
Management of Small Vessel Vasculitides 140
Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study 140
Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis 140
Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration 140
High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: Data from GISEA, the Italian biologics register 139
Early Lupus Project: one-year follow-up of an Italian cohort of patients with systemic lupus erythematosus of recent onset 139
FRI0110 Methotrexate monotherapy in real life: a drug survival analysis. comparison between very early arthritis and early arthritis cohorts 139
Splenic Infarction as Only Manifestation of Antiphospholipid Syndrome in a Patient With Rheumatoid Arthritis 138
Obesity and Inflammation – Targets for OA Therapy 138
Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome 138
Totale 17.062
Salva come PNG Salva come JPEG
Categoria #
all - tutte 206.866
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 206.866
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.917 0 0 0 0 109 185 163 146 153 171 344 646
2022/20233.717 575 439 289 301 364 495 78 433 545 28 108 62
2023/20241.250 105 260 58 98 105 267 38 60 15 47 32 165
2024/20256.640 145 91 482 157 139 616 635 774 335 405 1.000 1.861
2025/202615.643 1.967 622 910 1.691 1.861 931 1.697 529 1.463 1.508 458 2.006
2026/20274.984 648 909 1.048 2.164 215 0 0 0 0 0 0 0
Totale 48.755